In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Current devices and their application.

Session Update on percutaneous mitral valve options

Speaker Francesco Maisano

Event : ESC Congress 2013

  • Topic : imaging
  • Sub-topic : Echocardiography
  • Session type : Symposium

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Two columns page  

Update on percutaneous mitral valve options

Valvular Heart Diseases

 

Mitral regurgitation (MR) is a common valve lesion, particularly in the growing elderly population. Professor Iung (Paris, France) emphasised that surgery (preferably valve repair) is the recommended treatment gold standard but is underprovided, especially in high risk elderly patients, when the risk of intervention is felt unacceptable by the surgeon, cardiologist or patient. Percutaneous treatment options are therefore attractive in this cohort.
The Mitraclip device (which achieves an edge-to-edge repair akin to the Alfieri surgical procedure) has shown encouraging results in patients with organic MR within the EVEREST II study and in patients with functional MR in the ACCESS registries. A cautious approach to adoption of this technique in carefully selected patients has been advocated by the ESC guidelines on Valvular Heart Disease published in 2012.
Professor Maisano (Segrate, Italy) highlighted rapid progress with this technique, which now has an excellent safety and efficacy profile in well selected patients with suitable valvular anatomy.
Coronary sinus techniques have now been abandoned in favour of annuloplasty banding techniques, which carry a lower risk of complications. Further technological developments and creative solutions via the transapical approach (developed initially to facilitate transcatheter aortic valve implantation) include transapical mitral valve-in-valve and valve-in-ring procedures (Professor Holzhey, Leipzig, Germany), transcutaneous chordal replacement (Professor Seeburger, Leipzig, Germany) and transcutaneous mitral valve replacement (Professor Sondergaard, Copenhagen, Denmark). Careful development in animal models, innovative skills of interventional cardiologists and cardiac surgeons and further technological developments make this a rapidly evolving field.  Watch this space!!

References


920

SessionTitle:

Update on percutaneous mitral valve options

The content of this article reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

 

Members get more

Join now
  • 1ESC Professional Members – access all resources from general ESC events 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are